Cartesian Therapeutics, Inc. (RNAC)

NASDAQ: RNAC · USD

$6.70

+0.24 (+3.7%)· Recorded snapshot

Market cap	202.7M
Revenue (ttm)	1.5M
Net income (ttm)	-151.9M
EPS (ttm)	-$5.61
Shares out	30.3M
Volume	98,737
Beta	0.72

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 1.5M
Net income (ttm): -151.9M
EPS (ttm): -$5.61
Market cap: 202.7M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Hold

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/En/a

P25 n/aP50 n/aP75 n/a

Trailing P/En/a

P25 n/aP50 n/aP75 n/a

ROEn/a

P25 n/aP50 n/aP75 n/a

ROICn/a

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All RNAC indicators

Market & fundamental data

Available fields

184

Groups with data

Currency

USD

Showing 184 of 184 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001453687
Company name	Cartesian Therapeutics, Inc.
Country	United States
Country code	US
CUSIP number	816212302
Earnings date	2026-11-09
Earnings time	bmo
Employees	75
Employees change	9
Employees growth	13.64%
Enterprise value	$119M
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	2007
In index	RUSSELL2000
Industry	Biotechnology
IPO date	2016-06-22
Is primary listing	Yes
Is SPAC	No
ISIN number	US8162123025
Last 10-K release date	2026-03-09
Last earnings date	2026-08-06
Last refreshed	2026-10-28
Last stock split date	2024-04-05
Last stock split type	Reverse
Market cap	$202.7M
Market cap category	Micro-Cap
Next earnings date	2026-11-09
Options	Yes
Price	$6.70
Price currency	USD
Sector	Healthcare
SIC code	2834
Stock price date	2026-10-28
Symbol	RNAC
U.S. state	Maryland
Website	https://www.cartesiantherapeutics.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	-83.76%
EV/Sales	76.65x
FCF / EV yield	-69.44%
FCF yield	-39.91%
Forward EV/Sales	257.01x
Forward P/S	447.15x
P/S ratio	133.35x
Sector forward P/E	23.56x
Sector P/E	50.08x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Operating margin	-6,679.69%
Pretax margin	-10,906.16%
Profit per employee	$-2M
Profitable quarters	1
Revenue per employee	$19,693
ROA	-17.43%
ROCE	-33.1%
SBC / revenue	625.59%
Tax / revenue	-622.41%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth (Q)	-8%
EPS growth years	0
Net income growth (Q)	-0.74%
Net income growth quarters	1
Net income growth years	0
Revenue growth	43.96%
Revenue growth 3Y	-76.29%
Revenue growth years	0

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-2.1M
Depreciation and amortization	$2.6M
EBIT	$-98.7M
EBITDA	$-96.1M
EPS	$-5.61
FCF per share	$-2.60
Financing cash flow	$65.9M
Free cash flow	$-78.6M
Free cash flow minus SBC	$-87.9M
Gross profit	$-66.9M
Income taxes	$-9.2M
Investing cash flow	$-2.1M
Net borrowing	$46M
Net cash flow	$-12.7M
Net income	$-151.9M
Operating cash flow minus SBC	$-85.8M
Operating income	$-98.7M
Revenue	$1.5M
Stock-based compensation	$9.2M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	-3.93
Book value per share	$-4.17
Goodwill	$48.2M
Interest coverage	-115.8
Long-term assets	$165M
Long-term liabilities	$423.3M
Net cash (debt)	$83.8M
Net cash / market cap	42.52%
Net cash growth	-43.02%
Piotroski F-Score	3
Property, plant and equipment	$16.4M
Shareholders' equity	$-125.2M
Tangible book value	$-267.3M
Tangible book value per share	$-8.90
Total assets	$318.6M
Total cash	$147.6M
Total debt	$63.9M
Total liabilities	$443.9M
WACC	6.46%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0
Current assets	$153.6M
Current liabilities	$20.6M
Current ratio	7.48
Net working capital	$-10.3M
Quick ratio	7.19
Working capital	$133.1M
Working capital turnover	0.01

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-9.55%
Dividend yield	0%
Shareholder yield	-9.55%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
150-day SMA	$7.82
1D price change	3.72%
1M price change	-12.01%
1M total return	-12.01%
1W price change	1.96%
1W total return	1.96%
1Y price change	-26.33%
1Y return CAGR	-26.34%
1Y total return	-26.33%
20-day SMA	$6.63
200-day SMA	$7.66
3M price change	-16.3%
3M total return	-16.3%
50-day SMA	$7.88
50-day SMA vs 200-day SMA	50over200
52-week high	$11.00
52-week high date	2026-06-24
52-week low	$5.60
52-week low date	2026-03-27
6M price change	-8.04%
6M total return	-8.04%
All-time high	$42.60
All-time high date	2023-11-27
All-time low	$5.60
All-time low date	2026-03-27
Average true range (ATR)	$0.40
Average volume	141.7K
Beta (1Y)	3.06
Beta (2Y)	2.77
Beta (5Y)	0.72
Change from 52-week high	-39.09%
Change from 52-week low	19.64%
Change from all-time high	-84.69%
Change from all-time low	16.43%
Change from open	3.08%
Day's gap	0.62%
Dollar volume	$661,538
High price	$6.70
Low price	$6.46
Monthly RSI	35.98
Open price	$6.50
Position in 52-week range	100%
Premarket change	-2.32%
Premarket close	$6.46
Premarket price	$6.31
Previous close	$6.46
Price vs 150-day SMA	-16.61%
Price vs 20-day SMA	-1.6%
Price vs 200-day SMA	-14.85%
Price vs 50-day SMA	-17.28%
Relative volume	0.7
RSI	41.46
Sharpe ratio	-0.02
Sortino ratio	0.05
Volume	98.7K
Weekly RSI	42.3
YTD price change	-9.57%
YTD total return	-9.57%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	11.5M
Float percentage	37.97%
Shares change (QoQ)	11.35%
Shares change (YoY)	9.55%
Shares held by insiders	53.31%
Shares held by institutions	21.55%
Shares outstanding	30.3M
Short % of float	16.15%
Short % of shares	6.13%
Short ratio	14.6 days

Deeper analysis on RNAC

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this RNAC report

Is a complete RNAC research report available?

No complete published report is available for Cartesian Therapeutics, Inc. (RNAC) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

Cartesian Therapeutics, Inc. (RNAC)

Price

Financial snapshot

Fair-value bridge

Latest news · RNAC

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All RNAC indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on RNAC

Frequently asked questions